Cantor Fitzgerald Maintains Overweight on Ultragenyx Pharmaceutical, Raises Price Target to $115
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Kristen Kluska maintains an Overweight rating on Ultragenyx Pharmaceutical (NASDAQ:RARE) and raises the price target from $107 to $115.
May 31, 2024 | 2:36 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald has maintained an Overweight rating on Ultragenyx Pharmaceutical and increased the price target from $107 to $115, indicating a positive outlook.
The increase in the price target from $107 to $115 by a reputable analyst firm like Cantor Fitzgerald suggests a positive outlook for Ultragenyx Pharmaceutical. This is likely to boost investor confidence and could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100